ProKidney (PROK) UBS Virtual Organ Restoration and Cell Therapy Day summary

Company overview and technology

• Publicly traded biotech with ~200 employees, offices in North Carolina and Boston, and a manufacturing facility in Winston-Salem.

• Main asset, rilparencel (formerly REACT), is an autologous cell therapy derived from a patient’s own kidney cells, processed and reinjected into the kidney cortex.

• Intellectual property originated from Boston Children's Hospital, with over a decade of preclinical and clinical development.

Preclinical and clinical development

• Early preclinical work identified specific renal cell layers associated with improved kidney outcomes and less inflammation.

• Transitioned from a fresh to a cryopreserved product, now used in both phase II and phase III trials.

• Ongoing research into the biological mechanism, with new data expected at ASN in the second half of 2025.

Disease landscape and positioning

• Standard of care for diabetic chronic kidney disease has advanced with four main drug classes, but late-stage patients still face limited options.

• Rilparencel is positioned as a rescue therapy for patients with advanced CKD (GFR <30), aiming to delay dialysis or transplant.

• Addresses unmet needs for patients, providers, and payers by potentially reducing progression to dialysis.